Yahoo
    Swiss - Delayed Quote CHF

    Basilea Pharmaceutica AG (BSLN.SW)

    70.80 -0.70 (-0.98%)
    At close: October 30 at 5:30:30 PM GMT+1
    Loading Chart for BSLN.SW
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    New Clinical Data Might Change The Case For Investing In Basilea Pharmaceutica Stock (SWX:BSLN)

    New Clinical Data Might Change The Case For Investing In Basilea Pharmaceutica Stock (SWX:BSLN)
    Simply Wall St. 4d ago
    Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs

    Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs
    GlobeNewswire 5d ago
    Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

    Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026
    GlobeNewswire 12d ago
    Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

    Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
    GlobeNewswire 1mo ago
    Basilea Pharmaceutica (SWX:BSLN) Lifts Guidance Following Strong Half Year Results, Is It Fully Valued?

    Basilea Pharmaceutica (SWX:BSLN) Lifts Guidance Following Strong Half Year Results, Is It Fully Valued?
    Simply Wall St. 2mo ago
    Basilea Pharmaceutica Ltd (XSWX:BSLN) (H1 2026) Earnings Call Highlights: Revenue Surges 14% ...

    Basilea Pharmaceutica Ltd (XSWX:BSLN) (H1 2026) Earnings Call Highlights: Revenue Surges 14% ...
    GuruFocus.com 2mo ago
    Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track

    Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
    GlobeNewswire 2mo ago
    Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

    Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
    GlobeNewswire 3mo ago
    Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting

    Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
    GlobeNewswire 6mo ago
    Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

    Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
    GlobeNewswire 2mo ago
    Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

    Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
    GlobeNewswire 7mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: